Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Endo Pharmaceuticals
Endo Pharmaceuticals
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Packaging
Endo recalls one lot of Edex
Endo Pharmaceuticals has recalled one lot of Edex (alprostadil for injection) 10mcg to the consumer level, due to lack of sterility assurance
New Chief Medical Officer at Endo
Craig Paterson takes responsibility for global clinical development strategies at the company
Finance
Endo buys portfolio of branded and generic products
Acquisition supports continued growth in South Africa and adds some 60 on-market products and nearly 70 R&D pipeline programmes
Finance
Endo to purchase Par Pharmaceutical for US$8.05bn
Expanding generics business, product portfolio, pipeline and manufacturing capabilities
Finance
Valeant increases offer for Salix to US$15.8bn in cash
Endo withdraws its offer for the US manufacturer of gastrointestinal drugs
Finance
Endo submits offer to purchase Salix Pharmaceuticals for about US$15.7bn
Higher bid than Valeant's offer of $14.5bn in February
Pharmaceutical
Endo announces changes to senior management team
To accelerate growth both organically and through corporate development activities
Subscribe now